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PURPOSE. We hypothesize that patients with type 1 diabetes (T1D) may have abnormal
retinal vascular responses before diabetic retinopathy (DR) is clinically evident. Optical
coherence tomography angiography (OCTA) was used to dynamically assess the retinal
microvasculature of diabetic patients with no clinically visible retinopathy.
METHODS. Controlled nonrandomized interventional study. The studied population
included 48 eyes of 24 T1D patients and 24 demographically similar healthy volunteers.
A commercial OCTA device (AngioVue) was used, and two tests were applied: (1) the
hypoxia challenge test (HCT) and (2) the handgrip test to induce a vasodilatory or vaso-
constrictive response, respectively. The HCT is a standardized test that creates a mild
hypoxic environment equivalent to a flight cabin. The handgrip test (i.e., isometric exer-
cise) induces a sympathetic autonomic response. Changes in the parafoveal superficial
and deep capillary plexuses in both tests were compared in each group. Systemic cardio-
vascular responses were also comparatively evaluated.
RESULTS. In the control cohort, the vessel density of the median parafoveal superficial and
deep plexuses increased during hypoxia (F1,23 = 15.69, P < 0.001 and F1,23 = 16.26, P <
0.001, respectively). In the T1D group, this physiological response was not observed in
either the superficial or the deep retinal plexuses. Isometric exercise elicited a significant
decrease in vessel density in both superficial and deep plexuses in the control group (F1,23
= 27.37, P < 0.0001 and F1,23 = 27.90, P < 0.0001, respectively). In the T1D group, this
response was noted only in the deep plexus (F1,23 = 11.04, P < 0.01).
CONCLUSIONS. Our work suggests there is an early impairment of the physiological retinal
vascular response in patients with T1D without clinical diabetic retinopathy.
Keywords: optical coherence tomography angiography, handgrip test, hypoxia challenge
test, retinal vascular reactivity, subclinical retinopathy
Diabetes mellitus and diabetic retinopathy (DR) in partic-ular are major public health challenges and a leading
cause of blindness in the working age population world-
wide.1,2 Before the first typical signs of DR are detected
on retinal examination, it is believed that substantial neural
retinal damage and subclinical microvascular changes have
already developed.3,4 In fact, there is cumulative evidence
of an altered neurovascular coupling early in the patho-
physiology of the disease. Previous studies using the laser
Doppler flowmeter, functional magnetic resonance imaging,
the dynamic vessel analyzer, and flicker electroretinography
suggest that this abnormal retinal vessels’ autoregulation is
associated with an increased risk of DR progression.4–9
Optical coherence tomography (OCT) angiography
(OCTA) is an extension of structural OCT with increasing
applications in both clinical and research settings. OCTA
technology uses infrared wavelengths to provide noninva-
sive high-contrast imaging of the retinal microvasculature
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with unprecedented resolution. It does so by detecting
motion contrast produced by moving red blood cells in
retinal vessels over sequential B-scans without any need for
a contrast injection. By examining serial images over time,
the generated final image clearly defines retinal vascular
plexuses.10–14
Recently, a few studies using OCTA have been reporting
structural quantitative changes (i.e., reduced vessel density
and increased foveal avascular zone area) in patients with
diabetes before clinically evident DR.15–20 However, little
is known about the possibility of using OCTA to eval-
uate individual functional retinal vascular changes. Our
group recently published a safe, reproducible and inexpen-
sive protocol to assess retinal microvasculature reactivity in
healthy subjects, detailing how OCTA technology is able to
detect retinal vasodilation and vasoconstriction in response
to two physiological conditions—mild hypoxia and isomet-
ric exercise, respectively.21
We hypothesize that patients with diabetes may have
altered physiological retinal vascular responses early in the
natural history of the disease. Therefore, OCTA was used to
dynamically study the retinal microvasculature of diabetic
patients with no visible signs of retinopathy, thus contribut-
ing to the understanding of the earliest processes of DR
development.
MATERIAL AND METHODS
Ethics and Informed Consent
Our research protocol follows the tenets of the Declaration
of Helsinki22 and was submitted and approved by the Ethics
Committee of Lisbon Academic Medical Center. Written,
informed consent was obtained from all participants after
detailing the aims, procedures and risks of the study. Two
standardized tests were applied: (1) the hypoxia challenge
test (HCT)23 and (2) the handgrip test.24 As recommended by
the Ethics Committee, to minimize ethical concerns regard-
ing the HCT, patients and volunteers recruited must have
had the intention to fly in the future. All safety recom-
mendations regarding the handgrip test were also followed
and the test was discontinued if necessary.24 Medical confi-
dentiality was assured. At any time, subjects could anony-
mously withdraw from the study. The study protocol has
been registered in the ISRCTN clinical studies online plat-
form with the number 98388473, available online at http:
//www.isrctn.com/ISRCTN98388473.
Study Design, Participants, and
Inclusion/Exclusion Criteria
A controlled nonrandomized interventional study was
conducted, including one group of patients with type 1
diabetes (T1D) without clinical signs of DR, and a demo-
graphically similar control group of healthy subjects.
Patients with T1D were recruited from an adult diabetes
outpatient clinic, and a demographically (age and sex) simi-
lar sample of healthy volunteers was selected as a control
group. An anonymous questionnaire was carried out, includ-
ing the following questions: age, sex, smoking-pack years,
known diseases and current chronic medication, previous
intraocular surgery or trauma, symptoms during previous
flights, and intention to fly in the future. Clinical data avail-
able from the electronic health records included demo-
graphic characteristics, time from T1D diagnosis, glycated
hemoglobin (HbA1c) level, current medication, comorbidi-
ties, and presence of microalbuminuria. Subjects were also
asked to abstain from alcohol and caffeine for at least
six hours before the study to reduce the possible auto-
nomic effects and measurement bias.25 Patients with T1D
were treated with rapid acting insulin analogues (contin-
uous subcutaneous insulin infusion [CSII]), or long- and
rapid-acting insulin analogues (multiple daily injections
[MDI]). All volunteers were asked not to eat or take insulin
(MDI) or insulin boluses (CSII) in the two hours preced-
ing the study to minimize its vasodilatory effects in the
observed vascular response.26 It was also confirmed before
the start of the experimental protocol that no diabetic
patient had hypoglycemia (<70 mg/dL) or level 1 hyper-
glycemia (>180 mg/dL). Last, to minimize the effect of
diurnal variations in the systemic and ocular measure-
ments, the individuals of each group were evenly distributed
among the scheduled morning and afternoon study
sessions.
Ophthalmic exclusion criteria for both groups were as
follows: the presence of significant lens opacities (Lens
Opacities Classification System III equal to or more stage 2),
diabetic retinopathy, high refractive error (spherical equiv-
alent below −6.50 or above +4.00 diopters), history of
glaucoma or ocular hypertension, neuro-ophthalmic disease,
and previous intraocular surgery. Systemic exclusion crite-
ria included the following: hypertension (defined as systolic
blood pressure higher than 140 mm Hg or diastolic blood
pressure higher than 90 mm Hg), medically treated hyper-
tension, nephropathy or other documented microvascular
complications, local or systemic inflammatory diseases, and
smokers of more than 20 cigarettes a day. Pregnant women
were also excluded.
Study Protocol
First, the study protocol was explained individually to
every subject, written consent was obtained, and the health
questionnaire was completed. Then, all subjects under-
went a complete ophthalmological examination includ-
ing best-corrected visual acuity, slit-lamp biomicroscopy
with fundoscopy, autorefraction (RK-5; Canon, Inc., Tokyo,
Japan), fundus photography (CR-2; Canon, Inc.), intraocu-
lar pressure measurement, and ocular biometry (Lenstar;
Haag-Streit Diagnostics, Köniz, Switzerland). Other base-
line measurements performed included arterial blood pres-
sure and pulse oximetry (Carescape V100; GE Healthcare,
Chicago, IL, USA). Room temperature was maintained at
22°C, and consistent mesopic conditions were maintained
throughout the study.
A commercial OCTA device was used (Avanti XR, version
2017.1.0.151; Optovue, Fremont, CA, USA), with an A-scan
rate of 70,000 A-Scan/s with 5-mm axial resolution and using
a split-spectrum amplitude-decorrelation angiography algo-
rithm, thus giving an enhanced signal-to-noise ratio of flow
detection. The device used also included the latest projection
artefact removal software, allowing for a more-precise anal-
ysis of the deep plexus. All examinations were performed
by an experienced technician at the determined timepoints
using the 6- × 6-mm standard protocol for macular OCTA
examination. Two repeated scans were performed—one at
baseline and another during the stress test. Vessel density
of the superficial and deep plexuses were assessed from the
en face angiograms by analyzing a predefined annulus with
an outer diameter of 3 mm and an inner diameter of 1 mm,
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corresponding to the parafoveal region. This vessel density
value was automatically generated using built-in AngioAn-
alytics. Only high-quality images (signal strength > 8/10,
focused, and without movement artefacts) were included in
the analysis. No subjects were excluded as a result of poor
imaging quality. However, and of note for future studies, it
is worth mentioning that because of the sustained isomet-
ric effort required during the handgrip test, a minority of
the volunteers found it difficult to keep a completely steady
position in the OCTA chinrest. This specific situation affected
the imaging mostly with movement artefacts, and the exami-
nations needed to be repeated once in four of the 48 subjects
(two in each group).
Vasodilatory Response–HCT. The physiological
response to hypoxia has been previously reported. Similarly
to the cerebral vasculature, retinal vessels respond to a
decrease in PaO2 with vasodilation and increase in blood
flow. This local autoregulatory adaptation contributes to
keep a rather stable oxygen pressure in the inner retina
until PaO2 levels are as low as 40 mm Hg.27–31
The following protocol has been described in detail in
a previous publication.21 Briefly, the HCT is a standard
test23 performed at sea level to create a normobaric hypoxic
environment by reducing the FiO2 and making it equivalent
to that of a flight cabin. The parameters monitored during
HCT include oxygen peripheral saturation, arterial pressure,
and continuous electrocardiography. As established by the
British Thoracic Society, the recommended HCT duration to
obtain stable conditions is 20 minutes. Accordingly, OCTA
was performed at baseline and then again 30 minutes after
HCT start (i.e., in plateau hypoxic conditions). All symp-
toms were recorded, and the test was stopped if medically
necessary.
Vasoconstrictive Response–Handgrip Test. It is
known that isometric exercise is used to evaluate sympa-
thetic autonomic response causing steady and safe increases
in heart rate and arterial blood pressure, along with physio-
logical peripheral vasoconstriction.24 In the retina, the blood
flow remains relatively unchanged until the mean ocular
perfusion pressure increases by 35% to 60% above baseline.
This is achieved through a local autoregulatory increase in
vascular resistance—i.e., retinal vasoconstriction.32–34
The following protocol has been described in detail in
a previous publication.21 In brief, subjects sit in front of
the OCTA device, with the forearm in neutral position, the
elbow flexed at approximately 90°, and the wrist with the
thumb facing upward. Using a Jamar hydraulic dynamome-
ter, the participants are asked to keep a steady contraction
of at least one third of the maximal calculated force. The
OCTA acquisition starts in the plateau phase, i.e., after 90
seconds, being completed for both eyes within the 3- to 5-
minute test period. The arterial pressure in the contralat-
eral arm is measured every 90 seconds. According to the
test recommendations, if a diastolic blood pressure reaches
values higher than 120 mm Hg or any adverse symptom is
registered, the test is immediately interrupted.
Primary and Secondary Outcomes
A comparative analysis for each group—T1D patients
and healthy controls—was undertaken for the following
outcomes: (1) parafoveal vessel density evaluated using
OCTA at baseline and during HCT; (2) parafoveal vessel
density evaluated using OCTA at baseline and during the
handgrip test; and (3) systemic cardiovascular response in
both scenarios.
Statistics
Sample size was calculated considering a 5% clinically signif-
icant difference in mean vessel density between groups and
a standard deviation of 5%. Considering a power of 90%,
an alpha value of 0.05, a minimum of 17 T1D patients and
controls should be included. To account for the attrition rate
and to maintain the power of the study, a total of 24 patients
were included in each group.
Statistical analysis was performed using STATA v14.1. A
repeated-measures analysis of variance (ANOVA) model was
used to assess differences between the baseline and stress
tests’ measurements. The skewness-kurtosis test was used to
assess the normal distribution of the variables considered,
and the inexistence of significant outlier values was also
confirmed. Equality of variances was investigated, and the
results were reported accordingly, applying the Greenhouse-
Geisser correction when variables’ variances were not
equal.35 A P value <0.05 was considered for statistical signif-
icance. To guarantee independent observations, only the
right eye of each patient was considered for analysis.
RESULTS
Demographics and Baseline Data
Forty-eight eyes of 24 healthy subjects and 24 T1D patients
without evidence of diabetic retinopathy were studied. In
the T1D group, the mean HbA1c value was 7.9% ± 1.4%
(range 6.2%–11.5%) and the mean time from the diagnosis
was 14.8 ± 9.7 years (range 2–36 years). Both groups were
similar with respect to the demographic and baseline charac-
teristics, including age, gender, arterial blood pressure, heart
rate, body mass index, ocular axial length, intraocular pres-
sure and best-corrected visual acuity (Table 1). Of note, and
as previously reported elsewhere,36,37 a baseline rarefaction
of the superficial and deep parafoveal plexuses was noted
in the group of patients with diabetes, even before clinically
evident retinopathy (Table 1).
Systemic Response
Hypoxia Challenge Test. The median peripheral
oxygen hemoglobin saturation decreased from 97% to 88%
in both groups (Table 2). Also, as expected, an increase in the
heart rate was noted in hypoxic conditions in both groups
to increase the cardiac output. The arterial blood pressure
changes were less notable, with a mild decrease in mean
arterial pressure noted in the control group and no signifi-
cant differences in T1D patients (Table 2).
Handgrip Test. As shown in Table 3, the handgrip test
was associated with a significant increase of the heart rate
and systolic and diastolic arterial blood pressure in both
groups.
Retinal Vascular Response
Hypoxia Challenge Test (Fig. 1). In the healthy
cohort, the median parafoveal vessel density in the super-
ficial plexus increased from 55.1 (53.1–56.4) in baseline
conditions to 56.5 (54.0–57.6) in hypoxia (F1,23 = 15.69, P
< 0.001). The median parafoveal vessel density in the deep
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TABLE 1. Demographic and Baseline Data
Control Type 1 Diabetes P Value
Age, mean (SD), years 31.8 (8.2) 36.9 (10.4) 0.07
Male/Female, n 10/14 10/14 1.00
SAP, mean (SD), mm Hg 117 (12) 117 (9) 0.85
DAP, mean (SD), mm Hg 78 (9) 77 (6) 0.13
Heart rate, median (IQR), beats/min 62 (58–67) 62 (56–71) 0.63
Body mass index, mean (SD), kg/m2 22.6 (3.0) 25.1 (3.9) 0.06
Axial length, mean (SD), mm 24.1 (0.9) 23.5 (1.0) 0.07
Intraocular pressure, mean (SD), mm Hg 13.3 (2.1) 14.6 (3.0) 0.14
Visual acuity, median (IQR), logMAR 0 (0–0) 0 (0–0) 0.45
Parafoveal vessel density, median (IQR)
Superficial plexus 55.1 (53.1–56.4) 53.1 (48.9–55.1) 0.016
Deep plexus 60.4 (59.3–61.8) 57.2 (53.3–60.0) < 0.001
HbA1c, mean (SD), % — 7.9 (1.4) —
Time since diagnosis, mean (SD) — 14.8 ± 9.7 —
P values obtained with Student’s t test, Wilcoxon rank-sum (Mann-Whitney) test or Pearson’s χ2 test, as appropriate. DAP, diastolic arterial
blood pressure; HbA1c, glycated hemoglobin, pressure; SAP, systolic arterial blood pressure; SD, standard deviation; IQR, interquartile range.
TABLE 2. Systemic Response to the Hypoxia Challenge Test
Control P Value Type 1 Diabetes P Value
O2 Hb saturation, median (IQR), %
Baseline 97 (97–98) — 97 (97–98) —
Hypoxia 88 (85–89) <0.0001 88 (86–89) <0.001
SAP, mean (SD), mm Hg
Baseline 117 (12) — 117 (9) —
Hypoxia 114 (10) 0.05 118 (11) 0.25
DAP, mean (SD), mm Hg
Baseline 78 (9) — 77 (6) —
Hypoxia 75 (10) 0.045 75 (7) 0.10
MAP, mean (SD), mm Hg
Baseline 91 (10) — 90 (6) —
Hypoxia 88 (9) 0.02 89 (8) 0.40
Heart rate, median (IQR), beats/min
Baseline 62 (58–67) — 62 (56–71) —
Hypoxia 74 (71–80) <0.001 79 (63–86) <0.001
P values (versus baseline) obtained with Student’s t test and Wilcoxon rank-sum (Mann-Whitney) test, as appropriate. DAP, diastolic arterial
pressure; Hb, hemoglobin; MAP, mean arterial blood pressure; SAP, systolic arterial pressure; SD, standard deviation; IQR, interquartile range.
plexuses also increased, from 60.4 (59.3–61.8) at baseline to
62.0 (59.9–62.8) during hypoxia (F1,23 = 16.26, P < 0.001;
Table 4).
In the T1D group, there were no statistically signifi-
cant differences during hypoxia for the superficial (F1,23 =
0.06, P = 0.81) or deep (F1,23 = 1.08, P = 0.31) parafoveal
plexuses.
Handgrip Test (Fig. 2). In the control group, isomet-
ric exercise elicited a significant decrease in vessel density in
both superficial (55.8 [53.5–56.9] to 54.1 [52.2–54.5], F1,23 =
TABLE 3. Systemic Response to the Handgrip Test
Control P Value Type 1 Diabetes P Value
SAP, mean (SD), mm Hg
Baseline 118 (11) — 123 (12) —
Handgrip 150 (18) <0.0001 155 (24) <0.0001
DAP, mean (SD), mm Hg
Baseline 75 (9) — 79 (9) —
Handgrip 102 (14) <0.0001 98 (13) <0.0001
MAP, mean (SD), mm Hg
Baseline 89 (9) — 94 (9) —
Handgrip 123 (13) <0.0001 122 (17) <0.0001
Heart rate, median (IQR), beats/min
Baseline 67 (64–73) — 62 (67–78) —
Handgrip 77 (71–85) <0.01 79 (68–87) <0.01
P values (versus baseline) obtained with Student’s t test and Wilcoxon rank-sum (Mann-Whitney) test, as appropriate.
DAP, diastolic arterial pressure; MAP,mean arterial blood pressure; SAP, systolic arterial pressure; SD, standard deviation; IQR, interquartile
range.
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FIGURE 1. Exemplar of the setup during the hypoxia challenge test and OCT-angiography examination (A, B) and macular en-face 6- ×
6-mm angiograms obtained in baseline conditions (C) and during the hypoxic test (D). The angiograms belong to the healthy volunteer
depicted in B. Vessel density increased in hypoxic conditions as expected. Image quality score and parafoveal vessel density are provided
according to the built-in angioanalytics software, as described in the Methods section.
TABLE 4. Retinal Vascular Response to the Hypoxia Challenge Test
Parafoveal Vessel Density, Median (IQR) Control P Value Type 1 Diabetes P Value
Superficial plexus
Baseline 55.1 (53.1–56.4) — 53.1 (48.9–55.1) —
Hypoxia 56.5 (54.0–57.6) <0.001 52.0 (50.0 - 54.2) 0.81
Deep plexus
Baseline 60.4 (59.3 - 61.8) — 57.2 (53.3 - 60.0) —
Hypoxia 62.0 (59.9 - 62.8) < 0.001 56.2 (54.4 - 57.9) 0.31
P values (versus baseline) obtained with ANOVA repeated-measures. IQR, interquartile range.
FIGURE 2. Exemplar of the setup during the handgrip test and OCT-angiography examination (A) and macular en-face 6- × 6-mm angiograms
obtained in baseline conditions (B) and during the handgrip test (C). The angiograms belong to a volunteer with type 1 diabetes with no
clinical evidence of diabetic retinopathy. The physiological decrease in vessel density during the handgrip test was not observed. Image
quality score and parafoveal vessel density are provided according to the built-in angioanalytics software, as described in the Methods
section.
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TABLE 5. Retinal Vascular Response to the Handgrip Test
Parafoveal Vessel Density, Median (IQR) Control P Value Type 1 Diabetes P Value
Superficial plexus
Baseline 55.8 (53.5—56.9) — 53.5 (51.1–55.4) —
Handgrip 54.1 (52.2—54.5) <0.0001 52.8 (48.7–54.8) 0.06
Deep plexus
Baseline 60.4 (58.7–61.2) — 58.5 (54.1–60.3)
Handgrip 57.1 (53.7–58.6) <0.0001 55.9 (52.5–60.3) <0.01
P values (versus baseline) obtained with ANOVA repeated-measures. IQR, interquartile range.
27.37, P < 0.0001) and deep (60.4 [58.7–61.2] to 57.1 [53.7–
58.6], F1,23 = 27.90, P < 0.0001) parafoveal plexuses.
In the T1D group, the expected vasoconstrictive response
with decrease in vessel density during the test was not
observed in the superficial plexus (F1,23 = 3.86, P = 0.06),
being noticed only in the deep (F1,23 = 11.04, P < 0.01)
parafoveal plexus (Table 5).
DISCUSSION
Our study used OCTA to dynamically study the retinal
microvasculature functional responses to mild hypoxia and
isometric exercise using two standardized tests—the HCT
and the handgrip test, respectively.
A protocol for this functional analysis using OCTA has
been previously reported in healthy subjects,21 and this work
replicated the same results in terms of retinal responses
to isometric exercise and mild hypoxia. Importantly, this
study is the first to use OCTA to document the impairment
of two physiological retinal vascular responses in patients
with diabetes before any clinical features of DR are evident.
Our sample of young patients with T1D lacked other vascu-
lar comorbidities, such as hypertension and atherosclerosis
that are likely to influence OCTA measurements. Thus the
changes identified are most likely due to diabetes-specific
factors influencing retinal vascular behavior.38
The retina is one of the most metabolically active tissues
in the body, and for its normal functioning an effec-
tive autoregulation is crucial.12 The lack of the expected
vascular response pattern to both stimuli—mild hypoxia
and isometric exercise—suggests there is an early impair-
ment of the retinal autoregulatory function in the diabetic
group. Our results are supported by previous findings of
preclinical structural and functional changes in patients
with diabetes.16–19,37,39 The altered retinal vascular response
that we observed also corroborates previous evidence on
the importance of neurovascular coupling dysfunction very
early in DR development. These studies used the laser
Doppler blood flowmeter, functional magnetic resonance
imaging, flicker electroretinography and the dynamic vessel
analyzer as devices to assess retinal vascular function.5–9,40
However, these tools are generally used for research-only
purposes and therefore not widely accessible in ophthal-
mology clinics. In our study we used OCTA technology,
which is increasingly available in clinical practices world-
wide and may be further optimized for this purpose. The
ability to evaluate individual functional responses has multi-
ple potential advantages. First, it overcomes the limitations
of interpreting single structural exams that may vary among
individuals, including predetermined OCTA metrics, such
as the foveal avascular zone.41 Also, the retinal functional
response may be a more sensitive marker to detect earlier
changes, when compared with a structurally normal OCT
scan or fluorescein angiography. This may well have poten-
tial implications when considering monitoring and manag-
ing the metabolic, systemic and ophthalmic manifestations
of the disease.42 We found a significantly altered vascular
response in subjects with type 1 diabetes before any clin-
ical evidence of diabetic retinopathy. This abnormal reti-
nal microvascular response may correspond to an earlier
marker of endothelial dysfunction or changes in the signal-
ing between the retina and the vessels (i.e., neurovascular
coupling),27,43,44 and we provide a novel way of studying it
noninvasively using modern OCTA technology.
Another interesting finding of our study is the notion that
the cardiovascular systemic response does not appear to
be significantly different between the groups. The circum-
stantial finding of a statistically significant decrease in the
arterial blood pressure of the healthy cohort during mild
hypoxia (which was not clearly observed in the diabetic
group) seems to have limited clinical meaning. However,
this may be worth clarifying in future studies. The iden-
tified abnormal regional retinal response suggests there is
an increased ability of OCTA to sensitively identify vascular
changes. As an innovative, noninvasive, and safe technology,
able to study a central nervous system (i.e., retinal) microvas-
culature, OCTA is also becoming a useful tool for the study
of nonophthalmic conditions. Multiple reports have been
published with OCTA applications mainly in neurodegener-
ative conditions (e.g., Parkinson, Alzheimer’s, multiple scle-
rosis), but also in other diseases.45–52 Therefore studying a
patient’s retinal vascular responses can be a useful adjunct
to routine structural anatomical evaluation with interesting
application also in other medical specialties. This study high-
lights the potential to adapt the available OCTA technology
to combine this form of functional analysis to the currently
available structural angiogram.
With this study, we have demonstrated an attenuated reti-
nal vascular response in patients with type 1 diabetes with
no clinical evidence of ocular disease. However, these find-
ings should be interpreted along with the limitations of
our study. Although well-powered for the main outcomes,
the young age group, Caucasian population and relatively
small sample size may limit the external validity of the
study and also the possibility of multivariate analysis with
certain demographics and subgroup features. Also, the diur-
nal changes of the systemic and ocular variable analyzed
were minimized as possible but should not be excluded
as a potential source of bias. Despite careful recruitment,
the wide range of diabetes’ duration in our sample may
suggest the underestimation of the diabetic retinopathy
status, because some patients would be above the usual
time for the early manifestations of DR (such as peripheral
hemorrhages, microaneurysms, or both),53 that could have
been underreported with our methodology. Larger studies,
including patients with a range of disease severity through
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the various ETDRS levels would be useful to add weight
to our findings. Second, although individuals with type 1
diabetes were selected to minimize the influence of any co-
pathologies and systemic medication in the vascular analy-
sis, a small number of subjects were under systemic medica-
tion (other than insulin): four patients were on levothyrox-
ine, two were on simvastatin, one patient was taking sertra-
line, and one patient was on mexazolam and levothyroxine.
The patients taking levothyroxine had normal thyroid func-
tion test results. Although unlikely to affect the observed
patterns of retinal vascular response, we acknowledge the
potential vascular effects of these drugs.54–57 Also, insulin is
inherently vasoactive.26 Despite being asked not to admin-
ister insulin boluses in the two hours preceding the OCTA
measurements to reduce its influence on our observations,
we should not exclude the potential for some degree of
measurement bias introduced by its cardiovascular effects.
Likewise, current blood glucose concentration itself may
have a significant vascular effect.58,59 Because this param-
eter was not systematically evaluated in both groups, it is
also a limitation of our study protocol that we were not able
to rigorously control the observed vascular response for the
current glycemia. Third, although widely used in clinics and
research, the OCTA technology is not yet optimized for these
functional analyses, and it should be remembered that this
technology measures perfused vessel densities, not absolute
blood flows. Last, to ensure that the protocol for dynamic
retinal microvasculature analysis is as reproducible as possi-
ble, we used the manufacturer’s default software for superfi-
cial and deep capillary plexuses analysis. Thus the inherent
bias related to segmentation and differences to other devices
and models should be considered.11 We are certain that this
study acts as a valuable contributor to the development of
the OCTA technology as a realistic tool in functional retinal
analysis.
In conclusion, we used OCTA technology in conjunc-
tion with standardized stress tests and observed an early
impairment in the physiological retinal vascular response in
patients with type 1 diabetes before any clinical evidence
of retinopathy. Further work is required to better delineate
the process of DR development and to develop tools that
optimize its clinical significance.
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